Neurocrine Biosciences publishes supplement on Classic Congenital Adrenal Hyperplasia in The Journal of Clinical Endocrinology & Metabolism.
Read more
Triumvira Immunologics reports promising Phase I/II results for TAC-T cells in Claudin 18.2+ advanced solid tumors at ASCO 2025.
Read more
Clarity's Cu-64 SAR-bisPSMA receives FDA Fast Track for prostate cancer imaging in biochemical recurrence.
Read more
PureHealth acquires 60% of Hellenic Healthcare Group, expanding its European presence in a USD 2.3 billion deal.
Read more
Tris Pharma's cebranopadol reduces post-surgery pain in Phase III trial, aiming for FDA approval to address opioid crisis.
Read more
FDA approves Leqembi for once every four weeks IV dosing in early Alzheimer's Disease treatment.
Read more
Bicara's ficerafusp alfa shows promising results in Phase 1/1b trial for Squamous Cell Carcinoma of the Anal Canal.
Read more
FDA accepts Alvotech and Teva's biosimilar applications for golimumab, targeting inflammatory conditions like Rheumatoid Arthritis.
Read more
Coya Therapeutics expands pipeline with COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 receptor agonist.
Read more
Neurocrine and Takeda amend collaboration for Osavampator, focusing on Major Depressive Disorder treatment development.
Read more
BioCardia to present CardiAMP Heart Failure trial results at ACC 2025, showcasing autologous cell therapy for Heart Failure with Reduced Ejection Fraction.
Read more
FDA approves LEQEMBI for Alzheimer's Disease with new IV maintenance dosing every four weeks.
Read more
ImmunoPrecise Antibodies develops AI-designed GLP-1 therapies for Type 2 Diabetes, enhancing efficacy and patient experience.
Read more
Veru's Enobosarm shows significant lean mass preservation in Phase 2b trial with WEGOVY for obesity.
Read more
FDA grants priority review to Merck's WELIREG for advanced Pheochromocytoma and Paraganglioma treatment.
Read more
FDA approves LEQEMBI for Alzheimer's Disease with new IV maintenance dosing every four weeks.
Read more
AbbVie partners with Neomorph to develop molecular glue degraders for Oncology and Immunology, with potential $1.64B in milestones.
Read more
Arctic Therapeutics secures €26.5M to advance dementia and inflammatory skin disease treatments.
Read more
ViaDerma opens Dubai office and nears product registration for topical antibiotics in India.
Read more
ENHERTU approved in U.S. for HER2 low/ultralow metastatic Breast Cancer after endocrine therapy progression.
Read more
Harness Therapeutics appoints Dr. Heather Preston as Chair, secures funding to advance Huntington's Disease program.
Read more
Akero's efruxifermin shows significant cirrhosis reversal in MASH, doubling stock value and boosting phase 3 prospects.
Read more
PAR Excellence acquires NotiSphere to enhance healthcare supply chain management and recall efficiency.
Read more
Flagship Pioneering partners with Cambridge institutes to boost biotech research and innovation.
Read more
BioAdaptives announces FINRA-approved dividend for common stock shareholders, reflecting gratitude and commitment to growth.
Read more
